Treatment outcome of clonal cytopenias of undetermined significance: a single-institution retrospective study

Blood Cancer J. 2021 Mar 1;11(3):43. doi: 10.1038/s41408-021-00439-x.

Authors

Affiliations

¹ Division of Hematology, Mayo Clinic, Rochester, MN, USA.
² Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
³ Department of Hematopathology, Mayo Clinic, Rochester, MN, USA.
⁴ Division of Hematology, Mayo Clinic, Rochester, MN, USA. alkali.aref@mayo.edu.

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Aged, 80 and over
Clonal Hematopoiesis / drug effects*
Female
Humans
Immunoglobulins, Intravenous / therapeutic use
Intercellular Signaling Peptides and Proteins / therapeutic use
Male
Middle Aged
Retrospective Studies
Rituximab / therapeutic use
Steroids / therapeutic use
Treatment Outcome
Young Adult

Substances

Immunoglobulins, Intravenous
Intercellular Signaling Peptides and Proteins
Steroids
Rituximab